Home/Pipeline/Saroglitazar (Lipaglyn/Magdrop)

Saroglitazar (Lipaglyn/Magdrop)

Non-alcoholic steatohepatitis (NASH)

Phase 3Active (Global trial)EVIDENCES IV (Trial ID not specified in source)

Key Facts

Indication

Non-alcoholic steatohepatitis (NASH)

Phase

Phase 3

Status

Active (Global trial)

Company

Zydus Lifesciences

About Zydus Lifesciences

Zydus Lifesciences is a mission-driven global pharmaceutical company dedicated to creating healthier, happier communities worldwide. Its strategy is built on a dual engine of deep expertise in complex generics and a robust innovation pipeline in novel chemical entities (NCEs), biologics, and vaccines. Key achievements include launching Lipaglyn, the first NCE from an Indian research pipeline, and pioneering biosimilars like Exemptia (adalimumab), while maintaining strong financial growth and a vast commercial footprint.

View full company profile

Therapeutic Areas

Cardio-Metabolic Inflammation and Immunology Neurosciences Oncology Rare Diseases Infectious Diseases

Other Non-alcoholic steatohepatitis (NASH) Drugs

Drug	Company	Phase	Status
ADI-PEG 20 (pegargiminase)	Polaris Pharma	Phase 2	Active
ORMD-0801	Oramed Pharmaceuticals	Phase 2	Active
PXL065	Poxel	Phase 2	Active